SAMANTHA STEINBRENNER: Open Payments
NPI 1073082665 · WILKES BARRE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$804 in 47 payments from 9 companies in 2025. Trend: 2023 $1,693 · 2024 $1,961 · 2025 $804
Food & beverage: $695Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 20 | $329 |
| ABBVIE INC. | 14 | $203 |
| Neurocrine BioSciences, Inc. | 5 | $91 |
| Alkermes, Inc. | 3 | $74 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $16 |
Products named: VRAYLAR, UZEDY, INGREZZA, ARISTADA, AUSTEDO XR, REXULTI, Auvelity, CAPLYTA.
Industry payments across PA — which companies pay providers there.
